J. Mel Sorensen

Dr. Sorensen has served as Director, Chief Executive Officer and President of Galera since 2012.

Dr. Sorensen serves on the board of several private biopharmaceutical companies as Chairman including OncoFusion Therapeutics, Esanik Therapeutics and Medsyn Biopharma LLC. He is an advisor to the Biomarkers Consortium of the National Institutes of Health.

Dr. Sorensen holds an M.B., B.Ch. and B.A.O. from University College, Dublin. Dr. Sorensen’s postgraduate education and work has been in the United States, including an internal medicine residency in St. Louis and medical oncology fellowship at the Mayo Clinic, seven years at the National Cancer Institute as Senior Investigator in the Cancer Therapy Evaluation Program and four years each with Bayer and GlaxoSmithKline. Dr. Sorensen served as Director, Chief Executive Officer and President of Ascenta Therapeutics from 2004 until he joined Galera.